Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

    Home > Events > Webinar topra expediting access to novel medicinal products in the us and eu

    2 min read

    Webinar | Expediting Access to Novel/Medicinal Products in the US and EU

    Regulatory Pathways Available to Speed Development and Approval

    shutterstock_360398336_Woman Working From Home_Blog_opt1200

    Veristat and TOPRA hosted a webinar on the topic of:

     

    Expediting Access to Novel/Medicinal Products in the United States and Europe

     

     

     

     


    What  You Will Learn

     

    Bringing novel medicinal products to market is a long, complex, and expensive process which requires drug developers to balance the need for rigorous testing with the goal of getting medicines quickly to patients who need them. To this end, both US and European regulatory agencies have developed expedited pathways to accelerate the approval process for therapies that treat serious conditions and unmet medical needs.  

    Veristat Regulatory experts will discuss how developers of such therapies can utilize some or multiple programs/pathways to accelerate approval in the US and Europe. This webcast will highlight the requirements, benefits, and procedures for following US pathways: Accelerated Approval, Breakthrough Therapy Designation, Fast Track, and Priority Review Designation.

    Then we will examine the similarities and differences to the EU pathways: Accelerated Assessment, Conditional Marketing Application (CMA), and Priority Medicines Scheme (PRIME). The discussion will culminate with real-world examples and success stories. 

     

    Our experts will share their experience, successes, and lessons learned on how to:

    • Understand when and how to apply for the following expedited pathways with FDA and European Regulatory Authorities:   
    1.  Breakthrough Therapy (BT)
    2.  Fast Track (FT)
    3.  Priority Review
    4.  Accelerated Approval 
    5.  Accelerated Assessment
    6.  Conditional Marketing Authorization (CMA)
    7.  PRIME  
    •  Consider real-world examples of increased efficiency with submitting pathways requests with FDA and EMA independently and simultaneously 


                            DOWNLOAD

      Open the Webinar Replay

      Video  Now

      HubDB_Card Image_TOPRA Webinar  April 2022

       

       

      Open the

      Presentation Now

       

     

     


     

    Meet the Speakers

     

    Mara Holinger

     Mara Holinger, PhD, RAC 
    Senior Vice President, Regulatory Affairs, Veristat 

    Mara.holinger@veristat.com 

     

    Mara Holinger provides pharmaceutical, biotech and medical device firms with strategic consulting to prepare their regulatory pathway, design their clinical program and trials, perform gap analysis for CMC and preclinical reporting and write regulatory applications.  Additionally, she is an expert in regulatory agency meeting preparation, moderation and logistical support, and services as an Authorized Regulatory Representative and US Agent.   Mara has written, reviewed or provided oversight for more than 20 Investigational New Drug Applications (INDs), multiple Orphan Drug Designation (ODD) applications, breakthrough designation applications, special protocol assessments, fast track applications and several New Drug Applications, including 505(b)(2).  

     

    Mara earned her Ph.D. in Molecular Microbiology from Tufts University School of Medicine and began her career as a lead scientist in anti-cancer research.      

     

    Xavier Luria

     

    Xavier Luria, MD 

    Vice President, Regulatory Affairs Europe, Veristat

    xavier.luria@veristat.com

     

    Xavier Luria, MD, is responsible for providing strategic and implementation counsel across the spectrum of global regulatory and pharmacovigilance services for drugs, IVDs, and medical devices. Levering his deep expertise, Dr. Luria drives productive communication with health authorities and associated meetings and submissions, along with overseeing the development of impeccable project regulatory documentation and safety reporting. 


    Dr. Luria has nearly a decade of experience offering regulatory consulting within the industry, 7 years of experience working as Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), and spent the prior 18 years in the pharmaceutical industry.    

     

    In addition to Dr. Luria’s specialty in internal medicine, and pharmaceutical medicine and biostatistics (University Autonomous Barcelona), he has developed expertise in several specific therapeutic areas, carried out postgraduate qualification in clinical pharmacology, drug development, and regulation (Tufts University School of Medicine, Boston), and he is a recognized expert on regulatory systems and benefit-risk assessment (modeling, development, and methodologies).

     

    Kevin Hennegan

    Kevin Hennegan, MA,

    Director of US Regulatory Affairs, Veristat 

    Kevin.hennegan@veristat.com 

     

    Kevin Hennegan has provided strategic clinical and regulatory guidance to the pharmaceutical, biotech, and medical device industry for over 15 years. He has led and participated in the preparation of many successful FDA filings, including Investigational New Drug Applications (INDs), New Drug Applications (NDAs), Biologics License Applications (BLAs), Breakthrough Therapy Designations, Orphan Drug Designations, and Fast Track Applications. His experience covers a wide array of therapeutic indications (oncology, neurology, rheumatology, infectious disease, etc.) and product classes (therapeutic proteins, small molecule drugs, cell therapies, gene therapies, vaccines, and more). He is an advocate for patient-focused drug development and excels in engaging the FDA and other regulatory authorities as development partners. 

     

    Kevin earned a bachelor’s degree in Microbiology from Colorado State University and a master’s degree in Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder. 


     

     

     

     


    Learn More

     

    Share This Event:

       

    11 min read

    Monthly FDA Guidance and Regulatory News Review - September 2026

    This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...

    8 min read

    Monthly FDA Guidance and Regulatory News Review - August 2026

    This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...